1. Report Introduction 2. Diabetic Macular Edema (DME) 2.1. Overview 2.2. History 2.3. Diabetic Macular Edema (DME) Symptoms 2.4. Causes 2.5.Pathophysiology 2.6. Diabetic Macular Edema (DME) Diagnosis 2.6.1. Diagnostic Guidelines 3. Diabetic Macular Edema (DME) Current Treatment Patterns 3.1. Diabetic Macular Edema (DME) Treatment Guidelines 4. Diabetic Macular Edema (DME) - DelveInsight's Analytical Perspective 4.1. In-depth Commercial Assessment 4.1.1. Diabetic Macular Edema (DME) companies collaborations, Licensing, Acquisition -Deal Value Trends 4.1.1.1. Assessment Summary 4.1.2. Diabetic Macular Edema (DME) Collaboration Deals 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis 4.1.2.3. Diabetic Macular Edema (DME) Acquisition Analysis 5. Therapeutic Assessment 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development 5.1.2. Assessment by Product Type (Mono / Combination) 5.1.2.1. Assessment by Stage and Product Type 5.1.3. Assessment by Route of Administration 5.1.3.1. Assessment by Stage and Route of Administration 5.1.4. Assessment by Molecule Type 5.1.4.1. Assessment by Stage and Molecule Type 5.1.5. Assessment by MOA 5.1.5.1. Assessment by Stage and MOA 5.1.6. Assessment by Target 5.1.6.1. Assessment by Stage and Target 6. Diabetic Macular Edema (DME) Late Stage Products (Phase-III) 7. Diabetic Macular Edema (DME) Mid Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. Diabetic Macular Edema (DME) Discontinued Products 13. Diabetic Macular Edema (DME) Product Profiles 13.1. Drug Name: Company 13.1.1. Product Description 13.1.1.1. Product Overview 13.1.1.2. Mechanism of action 13.1.2. Research and Development 13.1.2.1. Clinical Studies 13.1.3. Product Development Activities 13.1.3.1. Collaboration 13.1.3.2. Agreements 13.1.3.3. Acquisition 13.1.3.4. Patent Detail 13.1.4. Tabulated Product Summary 13.1.4.1. General Description Table Detailed information in the report? 14. Diabetic Macular Edema (DME) Key Companies 15. Diabetic Macular Edema (DME) Key Products 16. Dormant and Discontinued Products 16.1. Dormant Products 16.1.1. Reasons for being dormant 16.2. Discontinued Products 16.2.1. Reasons for the discontinuation 17. Diabetic Macular Edema (DME) Unmet Needs 18. Diabetic Macular Edema (DME) Future Perspectives 19. Diabetic Macular Edema (DME) Analyst Review 20. Appendix 21. Report Methodology 21.1. Secondary Research 21.2. Expert Panel Validation

Table 1: Diabetic Macular Edema (DME) Diagnostic Guidelines Table 2: Diabetic Macular Edema (DME) Treatment Guidelines Table 3: Assessment Summary Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis Table 5: Diabetic Macular Edema (DME) Acquisition Analysis Table 6: Assessment by Phase of Development Table 7: Assessment by Product Type (Mono / Combination) Table 8: Assessment by Stage and Product Type Table 9: Assessment by Route of Administration Table 10: Assessment by Stage and Route of Administration Table 11: Assessment by Molecule Type Table 12: Assessment by Stage and Molecule Type Table 13: Assessment by MOA Table 14: Assessment by Stage and MOA Table 15: Assessment by Target Table 16: Assessment by Stage and Target Table 17: Diabetic Macular Edema (DME) Late Stage Products (Phase-III) Table 18: Diabetic Macular Edema (DME) Mid Stage Products (Phase-II) Table 19: Diabetic Macular Edema (DME) Early Stage Products (Phase-I) Table 20: Pre-clinical and Discovery Stage Products Table 21: Inactive Products Table 22: Dormant Products Table 23: Discontinued Products Figure 1: Disease Overview Figure 2: History Figure 3: Symptoms Figure 4: Causes Figure 5: Pathophysiology Figure 6: Diagnostic Guidelines Figure 7: Treatment Guidelines Figure 8: Diabetic Macular Edema (DME) companies collaborations, Licensing, Acquisition -Deal Value Trends Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis Figure 10: Diabetic Macular Edema (DME) Acquisition Analysis Figure 11: Assessment by Phase of Development Figure 12: Assessment by Product Type (Mono / Combination) Figure 13: Assessment by Stage and Product Type Figure 14: Assessment by Route of Administration Figure 15: Assessment by Stage and Route of Administration Figure 16: Assessment by Molecule Type Figure 17: Assessment by Stage and Molecule Type Figure 18: Assessment by MOA Figure 19: Assessment by Stage and MOA Figure 20: Late Stage Products (Phase-III) Figure 21: Mid Stage Products (Phase-II) Figure 22: Early Stage Products (Phase-I) Figure 23: Pre-clinical and Discovery Stage Products Figure 24: Inactive Products Figure 25: Dormant Products Figure 26: Discontinued Products Figure 27: Unmet Needs